Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Corm
S
S
Biggio
V
V
Roche-Lestienne
C
C
Laï
J-L
JL
Yakoub-Agha
I
I
Philippe
N
N
Nicolini
F-E
FE
Facon
T
T
Preudhomme
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016313:Genes, abl; D014644:Genetic Variation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D014157:Transcription Factors / Q000235:genetics*
D000970:Antineoplastic Agents; D001549:Benzamides; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; C493728:RUNX1 protein, human; D014157:Transcription Factors; D000068877:Imatinib Mesylate